Pain Therapeutics, Inc.. The Company's principal activity is to develop novel drugs for use in pain management. It operates in the clinical development and commercialization of novel painkillers. In addition to Remoxy, a unique, abuse-resistant controlled-release oxycodone, the Company has three drug candidates in clinical programs, including a novel ... More

Pain Therapeutics, Inc.. The Company's principal activity is to develop novel drugs for use in pain management. It operates in the clinical development and commercialization of novel painkillers. In addition to Remoxy, a unique, abuse-resistant controlled-release oxycodone, the Company has three drug candidates in clinical programs, including a novel radio-labelled monoclonal antibody to treat metastatic melanoma, as well as PTI-202 and PTI-721. Pain Therapeutics is also working on a new treatment for patients with hemophilia.